International Journal of Endocrinology · Jun 8, 2026

TRIM27 Ubiquitinates and Degrades PPARγ to Promote Osteogenic Differentiation of BMSCs and Alleviate Osteoporosis

By Zhang L, Li J, Wu B

OBJECTIVE: This study elucidates the role of TRIM27 in osteogenic differentiation and osteoporosis pathogenesis, focusing on its regulatory mechanism through PPARγ. METHODS: TRIM27 expression was assessed during osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) via RT-qPCR and western blot. TRIM27 was knocked down (sh-TRIM27) or overexpressed (Lv-TRIM27) to evaluate its impact on alkaline phosphatase (ALP) activity, mineralization (Alizarin Red S staining), and osteogenic markers (COL1A1, OPN, and OCN). An ovariectomized (OVX) mouse osteoporosis model was established to analyze TRIM27 expression and bone microstructure (H&E staining). Co-immunoprecipitation (Co-IP) and cycloheximide chase assays identified TRIM27-PPARγ interactions and degradation dynamics. Rescue experiments combined sh-TRIM27 with PPARγ knockdown (sh-PPARγ) or the agonist rosiglitazone (ROZ). RESULTS: TRIM27 expression increased 2.1-fold during BMSC osteogenic differentiation but decreased in OVX mice (p < 0.01 vs. sham). TRIM27 overexpression enhanced ALP activity, mineralization, and osteogenic markers (p < 0.05), while knockdown exerted opposite effects. TRIM27 directly bound PPARγ and promoted its ubiquitin-mediated degradation. PPARγ knockdown reversed sh-TRIM27-mediated inhibition of osteogenesis. In OVX mice, Lv-TRIM27 reduced bone loss by suppressing PPARγ, whereas ROZ abolished this protective effect. CONCLUSION: TRIM27, as a key osteogenic promoter, ameliorates osteoporosis by targeting the degradation of PPARγ. Our research reveals the potential of TRIM27 in treating bone metabolism disorders and may become a potential target for the treatment of osteoporosis.

doi.org/10.1155/ije/6777760Open accessPubMed 42267188Mechanisms

AgingResearch.News